Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490161 | 0.78 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL20995934 | 0.78 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13407243 | 0.77 | ALDH1A1 (0.34) | OPRM1ALDH1A1SMN1; SMN2OPRK1OPRD1 | |
| SCHEMBL13407297 | 0.77 | ALDH1A1 (0.34) | OPRM1ALDH1A1SMN1; SMN2OPRK1OPRD1 | |
| SCHEMBL13266563 | 0.77 | ALDH1A1 (0.34) | OPRM1ALDH1A1SMN1; SMN2OPRK1OPRD1 | |
| SCHEMBL13407356 | 0.77 | ALDH1A1 (0.34) | OPRM1ALDH1A1SMN1; SMN2OPRK1OPRD1 | |
| SCHEMBL12212559 | 0.75 | PKM (0.38) | OPRM1ALDH1A1PKM | |
| SCHEMBL18834876 | 0.75 | PKM (0.38) | OPRM1ALDH1A1PKM | |
| SCHEMBL22970027 | 0.75 | PKM (0.38) | OPRM1ALDH1A1PKM | |
| SCHEMBL20096125 | 0.75 | PKM (0.38) | OPRM1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | OPRM1 476/4885ALDH1A1 2867/4885PKM 2488/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | OPRM1 482/4885ALDH1A1 3058/4885PKM 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.